Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetes

Pancreas

Volumn 35, Issue 1, 2007, Pages 73-79

  Gault, Victor A ^a   McClean, Paula L ^a   Irwin, Nigel ^a   Power, Gavin J ^a   McCluskey, Janie T ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Diabetes; GIP agonist; Glucose homeostasis; Glucose dependent insulinotropic polypeptide (GIP); Streptozotocin

Indexed keywords

BROXURIDINE; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; N ACETYLGLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; POLYPEPTIDE; SOMATOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; SOMATOSTATIN RELEASE; STREPTOZOCIN DIABETES; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; SOMATOSTATIN;

EID: 34250763766     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e31804fa19a     Document Type: Article

References (35)

1. Meier JJ, Nauck MA, Schmidt WE, et al. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept. 2002;107:1-13.
2. Fehmann HC, Goke R. Characterisation of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription. Peptides. 1995;16:1149-1152.
3. Trumper A, Trumper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signalling. Mol Endocrinol. 2001;15:1559-1570.
4. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signalling by glucose-dependent insulinotropic polypeptide in beta(INS-1) cells. J Endocrinol. 2002;174:233-246.
5. Vella A, Rizza RA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res. 2004;36:830-836.
6. Gault VA, O'Harte FPM, Flatt PR. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides. 2003;37:253-263.
7. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept. 2005;128:117-124.
8. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.
9. Gault VA, Parker JC, Harriott P, et al. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol. 2002;175:525-533.
10. Deacon CF, Plamboeck A, Rosenkilde MM, et al. GIP(3-42) does not antagonise the insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol. 2006;291:E468-E475.
11. Parker JC, Lavery KS, Irwin N, et al. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. J Endocrinol. 2006;191:93-100.
12. 1- modified enzyme resistant forms of GIP, is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. J Biochem. 2002;367:913-920.
13. 2-substituted analogues of glucose-dependent insulinotropic polypeptide. J Endocrinol. 2003;176:133-141.
14. 2-substituted analogs of GIP with preserved biological activity in vivo. Metabolism. 2003;52:679-687.
15. O'Harte FPM, Gault VA, Parker JC, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002;45:1281-1291.
16. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycaemic activity. Diabetes. 1999;48:758-765.
17. 2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 2002;51:656-661.
18. Gault VA, Flatt PR, O'Harte FPM. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun. 2003;308:207-213.
19. Irwin N, Green BD, Gault VA, et al. Degradation, insulin secretion and antihyperglycaemic actions of two palmitate-derivatised N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide (GIP). J Med Chem. 2005;48:1244-1250.
20. 37). Biol Chem. 2005;386:679-688.
21. Irwin N, Green BD, Mooney MH, et al. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide (GIP) suitable for once-daily administration in type 2 diabetes. J Pharmacol Exp Ther. 2005;314:1187-1194.
22. 37): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide (GIP) with improved antidiabetic potential. J Med Chem. 2006;49:1047-1054.
23. Irwin N, Clarke GC, Green BD, et al. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem Pharmacol. 2006;72:719-728.
24. Stevens JF. Determination of glucose by an automatic analyzer. Clin Chem Acta. 1971;32:199-201.
25. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia. 1981;20:573-577.
26. Green BD, Gault VA, O'Harte FPM, et al. Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Br J Diabetes Vasc Dis. 2005;5:131-140.
27. Meier JJ, Goetze O, Anstipp J, et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab. 2004;286:E621-E625.
28. Ehses JA, Casilla VR, Doty T, et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology. 2003;144:4433-4445.
29. Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept. 2005;128:149-157.
30. Bailey CJ, Flatt PR, Kwasowski P, et al. Gastric inhibitory polypeptide and the enteroinsular axis in streptozotocin diabetic mice. Diabetes Metab. 1986;12:351-354.
31. Freyse EJ, Knospe S, Becher T, et al. Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism. 1999;48:134-137.
32. Malendowicz LK, Macchi C, Nussdorder GG, et al. Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med. 2003;11:763-766.
33. 8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther. 2006;318:914-921.
34. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002;283:E745-E752.
35. Marenah L, McCluskey JT, Abdel-Wahab YH, et al. A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells expressing islet-specific genes and hormones. Biol Chem. 2006;387:941-947.